Insider Trading Activity For Audentes Therapeutics, Inc. (NASDAQ:BOLD)
Mary Newman , SVP of Audentes Therapeutics, Inc. (NASDAQ:BOLD) reportedly Sold 10,000 shares of the company’s stock at an average price of 20 for a total transaction amount of $200,000.00 SEC Form
Insider Trading History For Audentes Therapeutics, Inc. (NASDAQ:BOLD)
Analyst Ratings For Audentes Therapeutics, Inc. (NASDAQ:BOLD)
These are 3 Buy Ratings .
The current consensus rating for Audentes Therapeutics, Inc. (NASDAQ:BOLD) is Buy (Score: 3.00) with a consensus target price of $22.25 , a potential (4.26% upside)
Analyst Ratings History For Audentes Therapeutics, Inc. (NASDAQ:BOLD)
- On 8/15/2016 Cowen and Company Initiated Coverage of rating Outperform
- On 11/12/2016 Piper Jaffray Companies Set Price Target of rating Buy with a price target of $24.00
- On 5/1/2017 Leerink Swann Initiated Coverage of rating Outperform with a price target of $22.00
- On 5/15/2017 Wedbush Reiterated Rating Ourperform with a price target of $20.00
- On 8/16/2017 Evercore ISI Initiated Coverage of rating Outperform to Outperform with a price target of $23.00
Recent Trading Activity for Audentes Therapeutics, Inc. (NASDAQ:BOLD)
Shares of Audentes Therapeutics, Inc. closed the previous trading session at 21.34 up +0.62 2.99% with 83,024 shares trading hands.